New Delhi: Shilpa Medicare has announced the strategic partnership for a long-term development and commercial manufacturing agreement with NXI Therapeutics AG, Switzerland for a novel therapy targeting autoimmune and alloimmune disorders.The collaboration covers end-to-end support across the product lifecycle, including CMC development, process scale-up, GMP clinical supply, and long-term commercial manufacturing.The collaboration spans early development through commercialization, positioning Shilpa as a lifecycle partner for the program.The autoimmune and immune-modulation segment represents one of the fastest-growing therapeutic categories globally, driven by increasing prevalence and demand for targeted immunotherapies. By securing this mandate at an early stage, Shilpa enhances its participation in high-value, innovation-driven pipelines with scalable commercial potential.This partnership marks the third significant international development and manufacturing contract secured by Shilpa group, underscoring strengthening demand from Western biotech companies for its integrated R&D capabilities and advanced GMP manufacturing infrastructure.While financial terms remain confidential, the agreement includes milestone-linked expansion potential and may evolve into a multi-year commercial supply relationship, subject to successful clinical and regulatory progression.Also Read: Lupin Settles Mirabegron Patent Dispute With Astellas for USD 90 Million, Clears US SalesVishnukant Bhutada, Managing Director, Shilpa Medicare Limited, commented:“This collaboration reinforces Shilpa’s transformation into a strategic innovation partner for global biotech companies. Our integrated development and commercial manufacturing capabilities enable us to support complex assets across the full product lifecycle. We continue to see strong momentum in high-value biologics and specialty therapeutics, strengthening long-term growth visibility for our CDMO platform.”Dr. Ruben Herrendorff, CEO, NXI Therapeutics AG, added:“Shilpa’s scientific depth, quality systems, and scalable GMP manufacturing capabilities make them an ideal partner as we advance our immunomodulatory program toward clinical and commercial milestones.”With expanding biologics capabilities, advanced GMP facilities in India, and increasing global biotech engagements, Shilpa continues to strengthen its position as a trusted development and commercial manufacturing partner in high-growth therapeutic segments.Also Read: Torrent Pharma Completes JB Chemicals Acquisition, Becomes Promoter with 46.39% Stake